Friedman, H. S., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Sathornsumetee, S., Gururangan, S., … Reardon, D. A. (2008). Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology, 26(15_suppl), 2062–2062. https://doi.org/10.1200/jco.2008.26.15_suppl.2062

Friedman, H. S., A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. A. Quinn, and D. A. Reardon. “Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2062–2062. https://doi.org/10.1200/jco.2008.26.15_suppl.2062.

Friedman HS, Desjardins A, Vredenburgh JJ, Rich JN, Sathornsumetee S, Gururangan S, et al. Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology. 2008 May 20;26(15_suppl):2062–2062.

Friedman, H. S., et al. “Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM).” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 2062–2062. Crossref, doi:10.1200/jco.2008.26.15_suppl.2062.

Friedman HS, Desjardins A, Vredenburgh JJ, Rich JN, Sathornsumetee S, Gururangan S, Quinn JA, Reardon DA. Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):2062–2062.